Tislelizumab Plus FOLFOX Versus POF in the Treatment of Locally Advanced: a Multicenter, Open-label, Randomized Phase III Studyunresectable or Metastatic Gastric/Gastroesophageal Junction Adenocarcinoma

To compare the efficacy and safety of tislelizumab combined with FOLFOX or combined with POF in the treatment of locally advanced unresectable or metastatic gastric/gastroesophageal junction adenocarcinoma with CPS≥1

Trial Details

NCT ID

NCT06793917

Phase

PHASE3

Sponsor

Fujian Cancer Hospital

Status

RECRUITING

Cancer Type

Gastric Cancer

Interventions

Tislelizumab
Oxaliplatin injection
Levo-Leucovorin
5-fluorouracil
Paclitaxel

Locations (sample)

Fuzhou, Fujian, China|26.06139,119.30611

Key Eligibility Criteria

Patients with advanced unresectable, histologically confirmed adenocarcinoma of the gastric or gastroesophageal junction.
18-70yeas.
ECOG PS 0-1.
No previous chemotherapy (perioperative chemotherapy, six months after fluorouracil alone or one year after oxaliplatin or a combination of taxoid …

For full eligibility, visit ClinicalTrials.gov.

Check If You May Be Eligible

Trialify translates complex eligibility criteria into plain yes-or-no questions to help you understand if this trial might be right for you.

Find Gastric Cancer Trials on Trialify →